(Q36598122)

15 August 2017

1 reference

title

Cladribine: an investigational immunomodulatory agent for multiple sclerosis (English)

1 reference

15 August 2017

0 references

Julie A Brousil

1

1 reference

15 August 2017

Russel J Roberts

series ordinal

2

1 reference

15 August 2017

Amanda L Schlein

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

19 September 2006

1 reference

Annals of Pharmacotherapy

15 August 2017

1 reference

15 August 2017

40

1 reference

15 August 2017

10

1 reference

15 August 2017

1814-1821

1 reference

The controversy surrounding the pathogenesis of the multiple sclerosis lesion

15 August 2017

1 reference

Natural history of multiple sclerosis

21 January 2018

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

Cladribine for multiple sclerosis: review and current status

21 January 2018

1 reference

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

21 January 2018

1 reference

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy

21 January 2018

1 reference

Bioavailability and bacterial degradation of rectally administered 2-chloro-2'-deoxyadenosine.

21 January 2018

1 reference

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.

21 January 2018

1 reference

The clinical pharmacokinetics of cladribine

21 January 2018

1 reference

Development of cladribine treatment in multiple sclerosis

21 January 2018

1 reference

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

21 January 2018

1 reference

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

Escherichia coli and enteritis in Angola

21 January 2018

1 reference

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

21 January 2018

1 reference

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

Primary progressive multiple sclerosis : current and future treatment options

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H037

1 reference

15 August 2017

1 reference